PROGNOSTIC VALUE OF CLONOGENIC-ASSAY FOR INDUCTION AND DURATION OF COMPLETE REMISSION IN ACUTE MYELOGENOUS LEUKEMIA

  • 1 February 1987
    • journal article
    • research article
    • Vol. 1  (2) , 121-126
Abstract
The validity of an in vitro clonogenic drug sensitiviy assay to predict the induction and the duration of complete remission was evaluated in a group of 81 patients with acute myelogenous leukemia treated wtih chemotherapy including an anthracycline drug (daunorubicin or adriamycin) and cytosine arabinoside (Ara-C). The inhibition of bone marrow clonogenic leukemic cells by in vitro exposure to anthracyclines 10-5 and 10-6 M Ara-C 10-5 M, and daunorubicin 10-6 M + Ara-C 10-7 M was significantly correlated with the achievement of a complete remission, but not with the duration of remission. A high second plating efficiency was correlated with short duration of complete remission, reflecting the poor prognosis of a high self-renewal capacity.